A panel of outside advisers to the U.S. Food and Drug Administration (FDA) voted in favor of approving a preventative antibody treatment for respiratory syncytial virus (RSV) in newborns and infants. The unanimous vote by 21 members of the FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) ...